Altrafin AG Sells 34,450 Shares of Novo Nordisk A/S $NVO

Key Points

• Altrafin AG reduced its Novo Nordisk stake by 19.8% in the second quarter, selling 34,450 shares and retaining 139,963 shares valued at approximately $6.71 million.
• Analyst sentiment remains cautious: Novo Nordisk has a consensus “Hold” rating from analysts, with an average price target of $64.94, while recent concerns include flat Wegovy sales, pricing pressure and competition from Eli Lilly.
• Novo Nordisk continues to see growth opportunities through sustained demand for weight-loss medicines and the U.S. launch of once-weekly insulin Awiqli. Shares recently opened at $46.52, and the company reported quarterly revenue of $11.98 billion and EPS of $0.94.

Altrafin AG lessened its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 19.8% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 139,963 shares of the company's stock after selling 34,450 shares during the period. Novo Nordisk A/S makes up about 0.0% of Altrafin AG's holdings, making the stock its 22nd largest position. Altrafin AG's holdings in Novo Nordisk A/S were worth $6,710,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of NVO. Certuity LLC increased its stake in Novo Nordisk A/S by 3.6% during the 4th quarter. Certuity LLC now owns 5,052 shares of the company's stock valued at $257,000 after purchasing an additional 177 shares in the last quarter. Oakworth Capital Inc. raised its holdings in Novo Nordisk A/S by 41.6% during the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company's stock worth $31,000 after buying an additional 182 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after buying an additional 200 shares in the last quarter. Werba Rubin Papier Wealth Management grew its holdings in shares of Novo Nordisk A/S by 6.0% during the fourth quarter. Werba Rubin Papier Wealth Management now owns 4,270 shares of the company's stock valued at $217,000 after buying an additional 241 shares during the last quarter. Finally, CoreCap Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 4.7% during the second quarter. CoreCap Advisors LLC now owns 5,341 shares of the company's stock valued at $256,000 after buying an additional 242 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on NVO shares. Berenberg Bank set a $47.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday. Citigroup reissued a "neutral" rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Wall Street Zen lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, June 20th. HSBC restated a "hold" rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Finally, Weiss Ratings upgraded Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, August 5th. Four analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of "Hold" and an average target price of $64.94.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk CEO Mike Doustdar said demand for weight-loss medicines still has a “long runway,” arguing that GLP-1 adoption remains in its early stages and could ultimately reduce healthcare costs and improve productivity. Novo Nordisk CEO sees long runway for weight-loss drugs
• Positive Sentiment: Novo’s once-weekly basal insulin Awiqli is now available in the United States, expanding the company’s diabetes portfolio and providing a potential new commercial growth driver beyond obesity treatments. Awiqli now available in the US
• Positive Sentiment: Erste Group raised its 2026 earnings-per-share estimate for Novo Nordisk to $3.27 from $3.20, while bullish commentary argues that the company’s broader cardiometabolic pipeline is being undervalued. Analysts raise Novo Nordisk earnings estimates
• Neutral Sentiment: Novo Nordisk is suing Eli Lilly over weight-loss-drug advertising. Management says the lawsuit is intended to ensure fair competition, but the dispute also highlights the intensifying rivalry between the two leading obesity-drug companies. Novo Nordisk CEO defends lawsuit against Eli Lilly
• Negative Sentiment: Analysts cited flat Wegovy sales, pricing challenges, pipeline setbacks and the risk that Eli Lilly is pulling ahead in the oral obesity market. These concerns, combined with the Berenberg downgrade, are weighing on sentiment toward NVO. Berenberg cuts Novo Nordisk as Lilly takes the oral market

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $46.52 on Thursday. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The stock has a fifty day simple moving average of $47.24 and a two-hundred day simple moving average of $44.61. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The firm has a market cap of $207.71 billion, a price-to-earnings ratio of 11.37, a price-to-earnings-growth ratio of 4.30 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The firm had revenue of $11.98 billion for the quarter. Analysts anticipate that Novo Nordisk A/S will post 3.39 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be paid a $0.5786 dividend. This represents a yield of 254.0%. The ex-dividend date is Monday, August 17th. Novo Nordisk A/S's payout ratio is currently 42.79%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source